Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 229

Sort by

Sort Order Select

Journal Articles

Introduction to a review series on high-risk aggressive lymphoma

Laurie H. Sehn, Michael Hallek

Blood (2024) 144 (25): 2561–2562.

https://doi.org/10.1182/blood.2023020913

Published: 2024

Journal Articles

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Blood (2024) 144 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2024-212970

Published: 2024

Journal Articles

Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma (DLBCL)

Jean-Nicolas Champagne, Diego Villa, Alina S. Gerrie, Christopher P. Venner, Graham W. Slack, Pedro Farinha, Jeffrey W Craig, Laura Hilton, Kerry J. Savage, David W. Scott, Laurie H. Sehn

Blood (2024) 144 (Supplement 1): 109.

https://doi.org/10.1182/blood-2024-201819

Published: 2024

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett

Blood (2024) 144 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2024-197902

Published: 2024

Journal Articles

A Novel Genetics-Based Classification of Advanced Follicular Lymphoma Identifies Prognostic Subgroups Following Bendamustine-Rituximab Immunochemotherapy

Haya Shaalan, Fabian Frontzek, Ciare Louise Freeman, Andrew Lytle, Pedro Farinha, Waleed Alduaij, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Andrew P. Weng, Laurie H. Sehn, Christian Steidl, Laura Hilton, David W. Scott, Ryan Morin

Blood (2024) 144 (Supplement 1): 742.

https://doi.org/10.1182/blood-2024-204219

Published: 2024

Journal Articles

Utility of the Central Nervous System International Prognostic Index (CNS-IPI) in Patients with Primary Mediastinal B-Cell Lymphoma Treated with Rituximab-Containing Chemoimmunotherapy

Jiayu Yang, Anna R. Hayden, Diego Villa, Aixiang Jiang, Alina S. Gerrie, Christopher P. Venner, Pedro Farinha, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2024) 144 (Supplement 1): 574.

https://doi.org/10.1182/blood-2024-198794

Published: 2024

Journal Articles

Zelenirstat Nmt Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma and Acute Myelogenous Leukemia: Mechanistic Insights and Clinical Outcomes

Randeep Sangha, John Kuruvilla, Laurie H. Sehn, Michael Weickert, Erwan Beauchamp, Jay M. Gamma, Naveen Pemmaraju, Gautam Borthakur, Luc G. Berthiaume, John R. Mackey

Blood (2024) 144 (Supplement 1): 5791.

https://doi.org/10.1182/blood-2024-208480

Published: 2024

Journal Articles

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Blood (2024) 144 (Supplement 1): 1645.

https://doi.org/10.1182/blood-2024-194612

Published: 2024

Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Blood (2024) 144 (Supplement 1): 469.

https://doi.org/10.1182/blood-2024-197938

Published: 2024

Journal Articles

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Blood (2024) 144 (Supplement 1): 4407.

https://doi.org/10.1182/blood-2024-197897

Published: 2024

Journal Articles

Omission of Bleomycin in Limited Stage Classic Hodgkin Lymphoma Patients with a Negative PET Scan Following 2 Cycles of ABVD Is Associated with Comparable Outcomes and Reduced Pulmonary Toxicity

Jiayu Yang, Diego Villa, Alina S. Gerrie, Petter Tonseth, Don C. Wilson, Francois Benard, Graham W. Slack, Christopher P. Venner, Andrea C. Lo, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2024) 144 (Supplement 1): 461.

https://doi.org/10.1182/blood-2024-194858

Published: 2024

Journal Articles

COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Blood (2024) 144 (Supplement 1): 286.

https://doi.org/10.1182/blood-2024-211949

Published: 2024

Journal Articles

Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

Jean-Nicolas Champagne, Steven Huang, Rayan Ramadan, Christopher P. Venner, Khaled Ramadan, Laurie H. Sehn, Kerry J. Savage, Diego Villa, David W. Scott, Waleed Alduaij, Cynthia L. Toze, Alina S. Gerrie

Blood (2024) 144 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2024-198028

Published: 2024

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood blood.2024025454.

https://doi.org/10.1182/blood.2024025454

Published: 2024

Includes: Supplemental data

Journal Articles

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett J Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K Hilton, Pedro Farinha, Graham W. Slack, Jeffrey W Craig, Alina S. Gerrie, Ciara L Freeman, Andrew J Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood blood.2024025725.

https://doi.org/10.1182/blood.2024025725

Published: 2024

Includes: Supplemental data

Journal Articles

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Brett Collinge, Susana Ben-Neriah, Laura K. Hilton, Waleed Alduaij, Tracy Tucker, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Merrill Boyle, Barbara Meissner, Diego Villa, Alina S. Gerrie, Laurie H. Sehn, Kerry J. Savage, Ryan D. Morin, Andrew J. Mungall, Christian Steidl, David W. Scott

Blood (2024) 144 (15): 1611–1616.

https://doi.org/10.1182/blood.2024025603

Published: 2024

Includes: Supplemental data

Journal Articles

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

Blood (2024) 144 (5): 525–540.

https://doi.org/10.1182/blood.2024024251

Published: 2024

Includes: Supplemental data

Journal Articles

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Blood (2024) 143 (2): 152–165.

https://doi.org/10.1182/blood.2023021348

Published: 2024

Includes: Supplemental data

Journal Articles

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Blood (2023) 142 (Supplement 1): 3000.

https://doi.org/10.1182/blood-2023-178623

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 603.

https://doi.org/10.1182/blood-2023-173692

Published: 2023

NARROW

Introduction to a review series on high-risk aggressive lymphoma

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma (DLBCL)

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

A Novel Genetics-Based Classification of Advanced Follicular Lymphoma Identifies Prognostic Subgroups Following Bendamustine-Rituximab Immunochemotherapy

Utility of the Central Nervous System International Prognostic Index (CNS-IPI) in Patients with Primary Mediastinal B-Cell Lymphoma Treated with Rituximab-Containing Chemoimmunotherapy

Zelenirstat Nmt Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma and Acute Myelogenous Leukemia: Mechanistic Insights and Clinical Outcomes

Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study

Omission of Bleomycin in Limited Stage Classic Hodgkin Lymphoma Patients with a Negative PET Scan Following 2 Cycles of ABVD Is Associated with Comparable Outcomes and Reduced Pulmonary Toxicity

COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only